Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?

Area of Science:

• Oncology
• Immunology
• Virology

Background:

• Immunotherapy, particularly immune checkpoint inhibitors, has transformed cancer treatment.
• Most breast cancers, especially triple-negative breast cancer, are not responsive to current immunotherapies due to lack of tumor immunoreactivity.
• Novel therapeutic strategies are essential to broaden immunotherapy benefits for breast cancer patients.

Purpose of the Study:

• To review the current landscape of oncolytic virotherapy for breast cancer.
• To summarize pre-clinical and clinical findings on oncolytic virus efficacy and safety.
• To highlight the potential of oncolytic viruses as a systemic therapy for breast cancer.

Main Methods:

• Systematic review of pre-clinical studies on oncolytic viruses in breast cancer models.
• Analysis of clinical trial data investigating oncolytic virotherapy for breast cancer.
• Evaluation of the mechanisms of action and safety profiles of oncolytic viruses.

Main Results:

• Oncolytic viruses demonstrate potential in pre-clinical breast cancer models.
• Early clinical investigations show promise, but further evidence is required.
• Understanding mechanisms and optimizing systemic delivery are key areas for advancement.

Conclusions:

• Oncolytic virotherapy presents a promising avenue for treating breast cancer, particularly for immunotherapy-resistant cases.
• Further research into safety, efficacy, and systemic administration is crucial for clinical translation.
• Oncolytic viruses could expand the reach of immunotherapy in breast cancer care.